google-site-verification: googlec7193c3de77668c9.html

FDA approves first treatment for chronic hepatitis delta virus infection

[

FDA approves first treatment for chronic Hepatitis Delta Virus infection

The U.S. Food and Drug Administration has approved Hepcludex (bulevirtide‐gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or compensated cirrhosis. Approval of Hepcludex was granted to Gilead Sciences.

Hepcludex received priority review and was approved under the Accelerated Approval pathway. It also received Breakthrough Therapy Designation and Orphan‐Drug Designation. There is a boxed warning that discontinuation of Hepcludex may result in severe acute exacerbations of HDV and hepatitis B virus infection.

The approval was based on results from a Phase III trial in which participants were randomly assigned to immediate treatment with Hepcludex (8.5 mg once daily for 144 weeks) or to delayed treatment following a 48‐week observational period.

At week 48, the rate of undetectable HDV RNA (less than the lower limit of quantification of 50 IU/mL) was 20% in the Hepcludex group versus 0% in the delayed treatment group. At weeks 96 and 144, the rate of undetectable HDV RNA increased to 36 and 50%, respectively, in the Hepcludex group.

“Today’s approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA‐approved therapies available,” Wendy Carter, D.O., from the FDA Center for Drug Evaluation and Research, said in a statement.

“For individuals living with this chronic viral infection, this new treatment option offers hope in managing a disease that can rapidly progress to serious liver complications.”

Clinical categories

Infectious diseasesGastroenterology

Who’s behind this story?


Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries.

Full profile →


Andrew Zinin

Andrew Zinin

Master’s in physics with research experience. Long-time science news enthusiast. Plays key role in Science X’s editorial success.

Full profile →

Advertisements

Copyright © 2026 HealthDay. All rights reserved.

Citation:
FDA approves first treatment for chronic hepatitis delta virus infection (2026, June 5)
retrieved 5 June 2026
from https://medicalxpress.com/news/2026-06-fda-treatment-chronic-hepatitis-delta.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




Source link

Views: 1

See also  Genital herpes rising in England, despite overall drop in STIs

Check Also

CDC warns of parasite outbreak tied to Taco Bell lettuce in 5 states

[ The U.S. Centers for Disease Control and Prevention (CDC) is warning people not to …

Genetic study redefines a form of excessive sweating as a treatable neurological condition

[ An international research team led by Dr. Frank Bosmans (Vrije Universiteit Brussel) has discovered …

Extra SORLA protein shields brain connections from tau tangles in mouse models

[ An overabundance of SORLA protein protects against a number of biological processes linked to …

Leave a Reply

Available for Amazon Prime